for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lonza says 3 Moderna vaccine ingredient lines to be at capacity by end-June

ZURICH, April 29 (Reuters) - Three new Lonza production lines that manufacture ingredients for Moderna’s COVID-19 vaccine are due to be producing at capacity by the end of June, Chief Executive Pierre-Alain Ruffieux said on Thursday in an interview.

Ruffieux spoke to Reuters after Lonza extended a deal with Moderna to build three additional lines, doubling existing capacity in 2022.

Also in the interview, Lonza Chairman Albert Baehny said it remains “speculation” to say that the Basel-based company will fall short of production targets for Moderna in the second quarter, adding the quarter has only just begun and that Lonza is working to remedy staffing challenges. (Reporting by John Miller; Editing by Michael Shields)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up